

AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the Application. Claims 11 and 26 have been amended as follows: Underlines indicate insertions and ~~strikethroughs~~ indicate deletions.

Listing of Claims

Claims 1-10 (Cancelled)

11. **(Currently amended)** A method of detecting a level of an amino-terminally truncated CDP/Cux polypeptide in a sample, wherein said polypeptide is p75, produced by translation initiation in exon 21 of the CDP/Cux gene, and wherein said method comprises:

- (a) obtaining said sample;
- (b) contacting said sample with an antibody which binds to said p75 polypeptide; and
- (c) detecting said antibody bound to said p75 polypeptide.

Claims 12-15 (Cancelled)

16. **(Previously presented)** The method of claim 11, wherein said sample is derived from breast tissue from a patient having or suspected of having breast cancer.

17. **(Previously presented)** The method of claim 11, wherein said sample is derived from blood from a patient having or suspected of having acute myeloid leukemia (AML).

18. **(Previously presented)** The method of claim 16, wherein detection of p75 in said breast tissue identifies said patient as having breast cancer.

19. **(Previously presented)** The method of claim 17, wherein detection of p75 in said blood identifies said patient as having acute myeloid leukemia (AML).

Claims 20-25 **(Cancelled)**

26. **(Currently amended)** A kit for detecting a level of an amino-terminally truncated CDP/Cux polypeptide in a sample, wherein said polypeptide is p75, produced by translation initiation in exon 21 of the CDP/Cux gene, said kit comprising:

- a) a first vessel containing a reagent enabling the formation of an immune complex, wherein said immune complex comprises:
 - i) an antibody which recognizes said p75 polypeptide; and
 - ii) a p75 polypeptide;
- b) a second vessel containing a detecting reagent for identifying said immune complex.

27. **(Previously presented)** The kit of claim 26, wherein said detecting reagent is a second antibody conjugated to:

- a) an enzyme;
- b) a radioactive isotope;
- c) a fluorescent molecule;
- d) a chemiluminescent molecule; or
- e) a biotin molecule.

28. **(Previously presented)** The kit of claim 26, comprising guidelines for the detection of p75.